Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer’s disease
- 1 February 2001
- journal article
- review article
- Published by Elsevier in Biological Psychiatry
- Vol. 49 (3) , 279-288
- https://doi.org/10.1016/s0006-3223(00)01109-4
Abstract
No abstract availableKeywords
This publication has 58 references indexed in Scilit:
- Correlation of nicotinic binding with neurochemical markers in Alzheimer's diseaseJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1998
- Cholinesterase Inhibitors in the Treatment of Alzheimer??s DiseaseDrug Safety, 1998
- Nicotinic System Involvement in Alzheimer??s and Parkinson??s DiseasesDrugs & Aging, 1997
- Stable expression in HEK‐293 cells of the rat α3/β4 subtype of neuronal nicotinic acetylcholine receptorFEBS Letters, 1996
- Tacrine interacts with an allosteric activator site on α4β2 nAChRs in M10 cellsNeuroReport, 1996
- Epibatidine and ABT 418 reveal selective losses of α4β2 nicotinic receptors in Alzheimer brainsNeuroReport, 1995
- Physostigmine, galanthamine and codeine act as ‘noncompetitive nicotinic receptor agonists’ on clonal rat pheochromocytoma cellsEuropean Journal of Pharmacology: Molecular Pharmacology, 1995
- Kinetic Analysis of Regional (S)(-)11C-Nicotine Binding in Normal and Alzheimer Brains In Vivo Assessment Using Positron Emission TomographyAlzheimer Disease & Associated Disorders, 1995
- Reduced number of [3H]nicotine and [3H]acetylcholine binding sites in the frontal cortex of Alzheimer brainsNeuroscience Letters, 1986
- Cholinergic underactivity in human memory disordersLife Sciences, 1978